Inclusion Criteria:  Self-reported gay, bisexual or other man who has sex with men (inclusive of transgender men) or transgender woman Age ≥16 HIV seronegative, as documented by a 4th generation HIV antigen/antibody combination test performed within 14 days of baseline No symptoms of acute HIV seroconversion (fever, myalgias, arthralgias, malaise, headache, rash, pharyngitis and/or diarrhea that is otherwise unexplained) Meets clinical criteria for PrEP according to the prescribing clinician. Patients can be enrolled into the study regardless of whether they will be newly initiating PrEP, or are already receiving PrEP; those already receiving PrEP can be using any regimen (eg. daily TDF/FTC, on-demand TDF/FTC, daily TAF/FTC) as long as they are willing to transition to the study regimen of daily, oral TAF/FTC. eGFR >30ml/min Has adequate access to the internet to permit use of the mHealth platform Adequate facility in English to communicate with their provider  Exclusion Criteria:  Known hypersensitivity/allergy to TAF/FTC Actively participating in another interventional trial related to the delivery of PrEP or sexual health-related care Being unwilling or unable to perform self-collected pharyngeal and/or rectal swabs as part of routine PrEP care Potential to become pregnant Currently living in, or planning to move to a location that would render standard of care or ad hoc in-person visits to the study site impractical during the study period.